Vertex Stock Falls On Unusually High Volume (VRTX)
Vertex Pharmaceuticals (Nasdaq:VRTX) is trading at unusually high volume Friday with 7.6 million shares changing hands. It is currently at four times its average daily volume and trading down $6.27 (-12.4%).
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Vertex Pharmaceuticals (Nasdaq: VRTX) is trading at unusually high volume Friday with 7.6 million shares changing hands. It is currently at four times its average daily volume and trading down $6.27 (-12.4%) at $44.21 as of 1:45 p.m. ET.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Vertex has a market cap of $10.42 billion and is part of the health care sector and drugs industry. Shares are up 45.4% year to date as of the close of trading on Thursday. Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. The company has a P/E ratio of 24.4, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Vertex as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the company's profit margins have been poor overall. You can view the full Vertex Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.